V
Vivatides Therapeutics
Extrahepatic RNA therapeutics beyond the liver
About Vivatides Therapeutics
Vivatides Therapeutics is a biotechnology company founded in 2025, with operations in Suzhou, China and the Boston area (Woburn, Massachusetts), that develops RNA therapeutics designed to reach tissues beyond the liver. Traditional RNA medicines have largely been limited to liver-targeted applications because of delivery challenges; Vivatides has built a proprietary extrahepatic delivery platform spanning both siRNA and antisense oligonucleotides (ASO), with advances in ligand conjugation, delivery efficiency, tissue-targeting specificity and safety, and encouraging in vivo results. Combined with sequence-design and target-discovery capabilities, the platform supports a diversified pipeline aimed at large chronic indications such as hyperlipidemia and hypertension, as well as oncology. The company was founded by Dr Keming Zhou, and its leadership team includes experts from leading RNA therapeutics companies who have led or played key roles in multiple extrahepatic RNA programmes. Vivatides raised a seed round of about $10 million led by Apricot Capital in 2025, then on 10 April 2026 announced an oversubscribed $54 million Series A co-led by Qiming Venture Partners and a leading industry fund, with Highlight Capital, TF Capital and existing investor Apricot Capital. Proceeds fund preclinical optimisation and IND-enabling studies, pipeline progression toward the clinic and expansion of its global R&D and management teams. Sources: PR Newswire 10 Apr 2026; PharmCube (2025 seed).
Source: Dealroom company dataAt a glance
- Status
- Operational
- Employees
- 3
- Open positions
- None listed
- Industry
- Health
- Sub-industry
- BioTechnology
- Sector
- Drug Development, Genetics and genomics, RNA, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- B2B
- Links
News
Open roles
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| SEEDOther financing | Aug 2025 | $10M | $40M | Apricot Capital · Qiming Venture Partners | ↗ |
Growth signals
Vivatides Therapeutics's team grew 50% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Vivatides Therapeutics in the Woburn ecosystem
The Vivatides Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.
Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed2 investors entered at this stage
Apricot Capital
Qiming Venture Partners
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Vivatides Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Vivatides Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.







